MedTrace Logo

To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

NCT00790153 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2009-04-10

No results posted yet for this study

Summary

To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.

Conditions

Interventions

DRUG

Insulin

Insulin infusion given during 3 hours at one occasion.

DRUG

AZD1656

Single dose oral suspension given at one occasion.

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD, Prof · AstraZeneca R&D Mölndal

  • Linda Morrow, MD · Profil Institute for Clinical Research, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790153 on ClinicalTrials.gov